Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer
Status:
Recruiting
Trial end date:
2025-03-28
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety/tolerability efficacy of oncolytic
virotherapy combined with Tislelizumab plus lenvatinib for advanced pancreatic cancer
patients who were relapsed or refractory to standard therapy